NAD+: What the Research Actually Says

Research use only. Not for human consumption.

What it is

NAD+ (nicotinamide adenine dinucleotide) is a coenzyme found in every living cell. It does two big jobs: it’s a workhorse of energy metabolism, shuttling electrons in the redox reactions that turn food into usable cellular energy, and it’s the required co-substrate for two families of enzymes tied directly to aging biology — the sirtuins (SIRT1–7), NAD+-dependent deacetylases that regulate gene silencing, genome stability, metabolism, and longevity, and the PARPs, which consume NAD+ during DNA repair. Nature

The reason NAD+ became the darling of the longevity world is a single, well-supported observation: NAD+ availability declines with age, which reduces sirtuin activity and disrupts communication between the cell nucleus and the mitochondria. From there the thesis writes itself — restore NAD+, restore the machinery. It’s worth being precise about what’s actually sold, because three different molecules get lumped together: NAD+ itself (as IV infusions, injectables, or research powder), and its two precursors, NMN (nicotinamide mononucleotide) and NR (nicotinamide riboside), which the body converts into NAD+. Explorationpub

The animal data

The rodent literature is the engine of the hype, and it’s substantial. In mice, NAD+ precursor supplementation improves insulin sensitivity, mitochondrial function, and vascular health, and long-term NMN administration mitigated age-associated physiological decline. Upstream, overexpression of sirtuin genes has been shown to extend lifespan in yeast, worms, and flies across many studies. nihMDPI

The caveat is the same one that haunts this entire field: mouse-to-human translation for aging interventions is notoriously unreliable, and the doses, timelines, and inbred models used in rodent work don’t map cleanly onto a middle-aged human hoping to age slower.

The human data

This is where the honest picture diverges hardest from the marketing — and the first thing to notice is that most of the rigorous human evidence isn’t on NAD+ at all. It’s on the precursors.

On NR, the key trial is Martens 2018. In a crossover RCT, chronic NR supplementation was well tolerated and effectively raised NAD+ in healthy middle-aged and older adults, with the authors suggesting future trials should further assess a potential benefit for blood pressure and arterial stiffness — a hint worth studying, explicitly not a settled result. Science

On NMN, the flagship is Yoshino 2021 in Science. In 25 postmenopausal women with prediabetes who were overweight or obese, 10 weeks of NMN improved insulin-stimulated glucose disposal and muscle insulin signaling — a real, well-run finding. But two details rarely survive the trip to a supplement ad: the population was a specific clinical group, not healthy people chasing longevity, and a change in NAD+ content in the muscle itself was not actually detected. Other NMN trials looking at arterial stiffness came back null. NMNnih

Zoom out to the systematic reviews and the pattern is consistent. Human results are mixed — some NMN trials found no change in arterial stiffness, while the Martens NR trial found a modest reduction in systolic blood pressure. An earlier review of the field was blunter: of 36 human trials with published results, 17 reported beneficial outcomes and 12 reported no benefit to patients, most of them small and aimed at scattered conditions rather than aging as an endpoint. No human trial has demonstrated slowed aging, extended lifespan, or extended healthspan in any hard sense, and even for the brain, evidence that oral precursors raise NAD+ levels in the brain or engage neurodegenerative pathways is lacking. Bodynutrition + 2

And the direct NAD+ route — the IV drips and injectables sold hardest to the longevity crowd — is the least studied of everything here. Despite wide availability and a broad range of anecdotally reported benefits, there is a paucity of human data interrogating IV NAD+ as a treatment, and no trials to date have compared clinical outcomes between the different precursors or routes of administration. IV infusion reliably raises plasma NAD+; whether that buys any of the promised outcomes in humans is an open question. HealthspanHealthspan

The honest one-liner: you can reliably raise the number. Whether raising the number does anything for human aging hasn’t been shown — and most of the evidence that does exist isn’t even on NAD+, it’s on precursors, in small trials measuring surrogate markers.

Genuinely promising vs. overhyped

Genuinely promising: The underlying biology is real and unusually well-characterized. NAD+ is genuinely essential, the age-related decline is well-documented, and precursors demonstrably raise blood NAD+ in properly controlled trials. The metabolic signals — insulin sensitivity, vascular markers — are a legitimate research frontier. Of every compound in this series, NAD+ rests on the strongest mechanistic foundation.

Overhyped: “Reverses aging,” “cellular regeneration,” the IV drip framed as a fountain of youth. Moving a biomarker is not the same as extending healthspan, and that leap has not been made in humans. The specific format pushed hardest — injectable and IV NAD+ — carries the thinnest controlled evidence in the category, not the strongest.

Regulatory reality

NAD+ itself is not an FDA-approved drug for aging or any other condition. IV and injectable NAD+ are offered through wellness clinics and compounding pharmacies, outside both the drug-approval and dietary-supplement frameworks. NR is the settled one — a patented form has been FDA-notified, GRAS-affirmed, and manufactured under cGMP standards. Npanational

NMN’s status, by contrast, has been a three-year rollercoaster. In late 2022 the FDA determined NMN was excluded from the dietary-supplement definition under the drug-preclusion clause, because it had been authorized for investigation as a drug (MetroBiotech’s IND) before being lawfully marketed as a supplement — and retailers pulled it. After a Natural Products Association citizen petition and a 2024 lawsuit, the agency reversed course: in two letters dated September 29, 2025, the FDA confirmed NMN is not excluded from the dietary-supplement definition, a position it reaffirmed in December 2, 2025 letters reinstating NMN’s status. For a research vendor, none of this converts NAD+ into an approved therapeutic — the accurate frame remains research use only. Npanational + 2

Hype vs. Evidence rating: 3/5

The strongest mechanism in the series, and precursors that reliably do what they claim to a biomarker — but the anti-aging payoff people actually buy it for is unproven in humans, the outcome data is thin, mixed, and surrogate-based, and the injectable NAD+ marketed hardest to longevity buyers is the least-studied route of all. Real molecule, real decline, real biomarker movement — unproven real-world longevity benefit.

Research use only. Not for human consumption. This content is educational and does not constitute medical advice or dosing guidance.